A carregar...
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
Hodgkins’ lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphom...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Libertas Academica
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3256979/ https://ncbi.nlm.nih.gov/pubmed/22253553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6637 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|